Fragile histidine triad gene expression in primary prostate cancer and in an in vitro model

Prostate

Volumn 43, Issue 2, 2000, Pages 101-110

  Guo, Zongyou ^a   Johansson, Sonny L ^a   Rhim, Johng S ^b   Vishwanatha, Jamboor K ^a,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

FHIT; Gene expression; HPE cells; Primary tumors; Transformation

Indexed keywords

HISTIDINE;

ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSFORMATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ACID ANHYDRIDE HYDROLASES; BASE SEQUENCE; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; PROTEINS; TUMOR CELLS, CULTURED;

EID: 0034001925     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(20000501)43:2<101::AID-PROS4>3.0.CO;2-A     Document Type: Article

References (50)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
2. Carter BS, Steinberg GD, Beaty TH, Childs B, Walsh PC. Familial risk factors for prostate cancer. Cancer Surv 1991;11:5-13.
3. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1992;89:3367-3371.
4. Sanda MG, Beaty TH, Stutzman RE, Childs B, Walsh PC. Genetic susceptibility of benign prostatic hyperplasia [see comments]. J Urol 1994;152:115-119.
5. McLellan DL, Norman RW. Hereditary aspects of prostate cancer. Can Med Assoc J 1995;153:895-900.
6. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, Croce CM, Huebner K. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996;84:587-597.
7. Barnes LD, Garrison PN, Siprashvili Z, Guranowski A, Robinson AK, Ingram SW, Croce CM, Ohta M, Huebner K. Fhit, a putative tumor suppressor in humans, is a dinucleoside 5′,5‴-P1,P3-triphosphate hydrolase. Biochemistry 1996;35:11529-11535.
8. Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, Inoue H, Tornielli S, Pilotti S, DeGregorio L, Pastorino U, Pierotti MA, Ohta M, Huebner K, Croce CM. The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 1996;85:17-26.
9. Negrini M, Monaco C, Vorechovsky I, Ohta M, Druck T, Baffa R, Huebner K, Croce CM. The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res 1996;56:3173-3179.
10. Man S, Ellis IO, Sibbering M, Blamey RW, Brook JD. High levels of allele loss at the FHIT and ATM genes in non-comedo ductal carcinoma in situ and grade I tubular invasive breast cancers. Cancer Res 1996;56:5484-5489.
11. Druck T, Hadaczek P, Fu TB, Ohta M, Siprashvili Z, Baffa R, Negrini M, Kastury K, Veronese ML, Rosen D, Rothstein J, McCue P, Cotticelli MG, Inoue H, Croce CM, Huebner K. Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res 1997;57:504-512.
12. Siprashvili Z, Sozzi G, Barnes LD, McCue P, Robinson AK, Eryomin V, Sard L, Tagliabue E, Greco A, Fusetti L, Schwartz G, Pierotti MA, Croce CM, Huebner K. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA 1997;94:13771-13776.
13. Ji L, Fang B, Yen N, Fong K, Minna JD, Roth JA. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 1999;59:3333-3339.
14. Kaighn ME, Reddel RR, Lechner JF, Peehl DM, Camalier RF, Brash DE, Saffiotti U, Harris CC. Transformation of human neonatal prostate epithelial cells by strontium phosphate transfection with a plasmid containing SV40 early region genes. Cancer Res 1989;49:3050-3056.
15. Parda DS, Thraves PJ, Kuettel MR, Lee MS, Arnstein P, Kaighn ME, Rhim JS, Dritschilo A. Neoplastic transformation of a human prostate epithelial cell line by the v-Ki-ras oncogene. Prostate 1993;23:91-98.
16. Rhim JS, Webber MM, Bello D, Lee MS, Arnstein P, Chen LS, Jay G. Stepwise immortalization and transformation of adult human prostate epithelial cells by a combination of HPV-18 and v-Ki-ras. Proc Natl Acad Sci USA 1994;91:11874-11878.
17. Kuettel MR, Thraves PJ, Jung M, Varghese SP, Prasad SC, Rhim JS, Dritschilo A. Radiation-induced neoplastic transformation of human prostate epithelial cells. Cancer Res 1996;56:5-10.
18. Rhim JS, Jin S, Jung M, Thraves PJ, Kuettel MR, Webber MM, Hukku B. Malignant transformation of human prostate epithelial cells by N-nitroso-N-methylurea. Cancer Res 1997;57:576-580.
19. Dahiya R, McCarville J, Hu W, Lee C, Chui RM, Kaur G, Deng G. Chromosome 3p24-26 and 3p22-12 loss in human prostatic adenocarcinoma. Int J Cancer 1997;71:20-25.
20. Kumble KD, Hirota M, Pour PM, Vishwanatha JK. Enhanced levels of annexins in pancreatic carcinoma cells of Syrian hamsters and their intrapancreatic allografts. Cancer Res 1992;52: 163-167.
21. Panagopoulos I, Pandis N, Thelin S, Petersson C, Mertens F, Borg A, Kristoffersson U, Mittelman F, Aman P. The FHIT and PTPRG genes are deleted in benign proliferative breast disease associated with familial breast cancer and cytogenetic rearrangements of chromosome band 3p14. Cancer Res 1996;56: 4871-4875.
22. Powell SM, Petersen GM, Krush AJ, Booker S, Jen J, Giardiello FM, Hamilton SR, Vogelstein B, Kinzler KW. Molecular diagnosis of familial adenomatous polyposis. N Engl J Med 1993; 329:1982-1987.
23. Roest PA, Roberts RG, Sugino S, van Ommen OG, den Dunnen DJ. Protein truncation test (PTT) for rapid detection of translation-terminating mutations. Hum Mol Genet 1993;2:1719-1721.
24. Kumble KD, Vishwanatha JK. Immunoelectron microscopic analysis of the intracellular distribution of primer recognition proteins, annexin 2 and phosphoglycerate kinase, in normal and transformed cells. J Cell Sci 1991;99:751-758.
25. Isaacs WB, Bova GS, Morton RA, Bussemakers MJ, Brooks JD, Ewing CM. Molecular biology of prostate cancer progression. Cancer Surv 1995;23:19-32.
26. Isaacs WB, Bova GS, Morton RA, Bussemakers MJ, Brooks JD, Ewing CM. Genetic alterations in prostate cancer. Cold Spring Harbor Symp Quant Biol 1994;59:653-659.
27. Lalani N, Laniado ME, Abel PD. Molecular and cellular biology of prostate cancer. Cancer Metastasis Rev 1997;16:29-66.
28. Huebner K, Hadaczek P, Siprashvili Z, Druck T, Croce CM. The FHIT gene, a multiple tumor suppressor gene encompassing the carcinogen sensitive chromosome fragile site, FRA3B. Biochim Biophys Acta 1997;1332:M65-70.
29. Boldog F, Gemmill RM, West J, Robinson M, Robinson L, Li E, Roche J, Todd S, Waggoner B, Lundstrom R, Jaconson J, Mullakandov MR, Klinger H, Drabkin HA. Chromosome 3p14 homozygous deletions and sequence analysis of FRA3B. Hum Mol Genet 1997;6:193-203.
30. Zimonjic DB, Druck T, Ohta M, Kastury K, Croce CM, Popescu NC, Huebner K. Positions of chromosome 3p14.2 fragile sites (FRA3B) within the FHIT gene. Cancer Res 1997;57:1166-1170.
31. Shridhar V, Wang L, Rosati R, Paradee W, Shridhar R, Mullins C, Sakr W, Grignon D, Miller OJ, Sun QC, Petros J, Smith DI. Frequent breakpoints in the region surrounding FRA3B in sporadic renal cell carcinomas. Oncogene 1997;14:1269-1277.
32. Hendricks DT, Taylor R, Reed M, Birrer MJ. FHIT gene expression in human ovarian, endometrial, and cervical cancer cell lines. Cancer Res 1997;57:2112-2115.
33. Luan X, Shi G, Zohouri M, Paradee W, Smith KI, Decker HJ, Cannizzaro LA. The FHIT gene is alternatively spliced in normal kidney and renal cell carcinoma. Oncogene 1997;15:79-86.
34. Gemma A, Hagiwara K, Ke Y, Burke LM, Khan MA, Nagashima M, Bennett WP, Harris CC. FHIT mutations in human primary gastric cancer. Cancer Res 1997;57:1435-1437.
35. Hibi K, Taguchi M, Nakamura H, Hirai A, Fujikake Y, Matsui T, Kasai Y, Akiyama S, Ito K, Takagi H. Alternative splicing of the FHIT gene in colorectal cancers. Jpn J Cancer Res 1997;88: 385-388.
36. Sugimoto K, Yamada K, Miyagawa K, Hirai H, Oshimi K. Decreased or altered expression of the FHIT gene in human leukemias. Stem Cells 1997;15:223-228.
37. Mao L, Fan YH, Lotan R, Hong WK. Frequent abnormalities of FHIT, a candidate tumor suppressor gene, in head and neck cancer cell lines. Cancer Res 1996;56:5128-5131.
38. Virgilio L, Shuster M, Gollin SM, Veronese ML, Ohta M, Huebner K, Croce CM. FHIT gene alterations in head and neck squamous cell carcinomas. Proc Natl Acad Sci USA 1996;93:9770-9775.
39. Sozzi G, Alder H, Tornielli S, Corletto V, Baffa R, Veronese ML, Negrini M, Pilotti S, Pierotti MA, Huebner K, Croce CM. Aberrant FHIT transcripts in Merkel cell carcinoma. Cancer Res 1996; 56:2472-2474.
40. Pandis N, Bardi G, Mitelman F, Heim S. Deletion of the short arm of chromosome 3 in breast tumors. Genes Chromosomes Cancer 1997;18:241-245.
41. Yanagisawa K, Kondo M, Osada H, Uchida K, Takagi K, Masuda A, Takahashi T. Molecular analysis of the FHIT gene at 3p14.2 in lung cancer cell lines. Cancer Res 1996;56:5579-5582.
42. Shridhar R, Shridhar V, Wang X, Paradee W, Dugan M, Sarkar F, Wilke C, Glover TW, Vaitkevicius VK, Smith DI. Frequent breakpoints in the 3p14.2 fragile site, FRA3B, in pancreatic tumors. Cancer Res 1996;56:4347-4350.
43. Druck T, Hadaczek P, Fu TB, Ohta M, Siprashvili Z, Baffa R, Negrini M, Kastury K, Veronese ML, Rosen D, Rothstein J, McCue P, Cotticelli MG, Inoue H, Croce CM, Huebner K. Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res 1997;57:504-512.
44. Hendricks DT, Taylor R, Reed M, Birrer MJ. FHIT gene expression in human ovarian, endometrial, and cervical cancer cell lines. Cancer Res 1997;57:2112-2115.
45. Wistuba II, Montellano FD, Milchgrub S, Virmani AK, Behrens C, Chen H, Ahmadian M, Nowak JA, Muller C, Minna JD. Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma. Cancer Res 1997;57: 3154-3158.
46. Geurts JM, Schoenmakers EF, Roijer E, Stenman G, Van de Ven WJ. Expression of reciprocal hybrid transcripts of HMGIC and FHIT in a pleomorphic adenoma of the parotid gland. Cancer Res 1997;57:13-17.
47. Hayashi S, Tanimoto K, Hajiro Nakanishi K, Tsuchiya E, Kurosumi M, Higashi Y, Imai K, Suga K, Nakachi K. Abnormal FHIT transcripts in human breast carcinomas: a clinicopathological and epidemiological analysis of 61 Japanese cases. Cancer Res 1997;57:1981-1985.
48. Thiagalingam S, Lisitsyn NA, Hamaguchi M, Wigler MH, Wilson JK, Markowitz SD, Leach FS, Kinzler KW, Vogelstein B. Evaluation of the FHIT gene in colorectal cancers. Cancer Res 1996;56:2936-2939.
49. Zou TT, Lei J, Shi YQ, Yin J, Wang S, Souza RF, Kong D, Shimada Y, Smolinski KN, Greenwald BD. FHIT gene alterations in esophageal cancer and ulcerative colitis (UC). Oncogene 1997; 15:101-105.
50. Latil A, Bieche I, Fournier G, Cussenot O, Pesche S, Lidereau R. Molecular analysis of the FHIT gene in human prostate cancer. Oncogene 1998;16:1863-1868.